% for lesions with a mean length of 8.9 cm.211 The Zilver PTX trial randomly assigned 471 patients with SFA lesions averaging 6.5 cm to treatment with a paclitaxel DES
or PTA as a primary procedure and to BMS in a subset of
110 study patients who required further treatment for immediate failure of PTA alone. Patency at 1 year was 83.1%
for DES and